NCT04179890

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

UpSwinG: Real World Study on TKI Activity in Uncommon Mutations and Sequencing Giotrif®

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 462 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated with an EGFR-TKI

Conditions

• Non-squamous, Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Afatinib (Gi(l)otrif®)	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
DRUG	Erlotinib (Tarceva®)	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
DRUG	Gefitinib (IRESSA®)	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
DRUG	Osimertinib (Tagrisso®)	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
DRUG	Afatinib (Gi(l)otrif®)	As first line therapy.
DRUG	Osimertinib (Tagrisso®)	In the case the T790M resistance mutation was developed (second line therapy).

Timeline

• Start date: 2019-12-17
• Primary completion: 2021-07-22
• Completion: 2021-07-22
• First posted: 2019-11-27
• Last updated: 2023-05-25
• Results posted: 2023-05-25

Locations

1 site across 1 country: United Kingdom